Skip to content

Effects of Endovascular Thrombectomy on Cerebral Aß Deposition and Cognitive Impairment in Patients with Acute Ischemic Stroke Accompanied by Anterior Circulation Large Vessel Occlusion

Effects of Endovascular Thrombectomy on Cerebral Aß Deposition and Cognitive Impairment in Patients with Acute Ischemic Stroke Accompanied by Anterior Circulation Large Vessel Occlusion

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079242
Enrollment
Unknown
Registered
2023-12-28
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Endovascular thrombectomy group:Endovascular thrombectomy
Non endovascular thrombectomy group:Conventional drug treatment

Sponsors

The First Affiliated Hospital of Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 18-80 years old; meeting the diagnostic criteria for acute ischemic stroke (AIS), onset =24 hours, NIHSS = 8, and confirmation of responsible vessel occlusion in the middle cerebral artery M1 segment or internal carotid artery by MRA or CTA; first-ever AIS or previous history of AIS with pre-stroke mRS score = 1; meeting the indications for endovascular therapy as outlined in the "Chinese Guidelines for Early Endovascular Intervention in Acute Ischemic Stroke 2022"; consent form signed by the patient or legal representative.

Exclusion criteria

Exclusion criteria: Secondary intracerebral hemorrhage; critically ill, with estimated survival of less than 3 months; history of previous organic brain diseases such as traumatic brain injury, central nervous system infections, brain tumors, etc.; history of dementia or cognitive decline prior to AIS; diseases associated with Aß pathology: cerebral amyloid angiopathy, Parkinson's disease, Huntington's disease; inability to cooperate with cognitive function assessments, such as severe language or mental disorders; allergy to 11C-PIB imaging agent.

Design outcomes

Primary

MeasureTime frame
ß-amyloid in the brain;

Secondary

MeasureTime frame
Mini-mental State Examination;Montreal Cognitive Assessment ;Plasma ß-amyloid;

Countries

China

Contacts

Public ContactYusheng Zhang

The First Affiliated Hospital of Jinan University

zhangyushengjnu@163.com+86 189 2221 2857

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026